Medical Condition News

RSS

Risk for cardiovascular disease begins early in life

A new multi-national survey reveals the extent of misconceptions about when is the right time to start taking action to prevent cardiovascular disease (CVD). In a four-country survey sample of 4,000 adults, 49 per cent answered age 30 years or older when asked at what age they believe people should start to take action about their heart health to prevent conditions such as heart disease and stroke.

24 Sep 2012

Conceptually novel mechanism for biological regulation of cell suicide

Death plays a big role in keeping things alive. Consider the tightly orchestrated suicide of cells--a phenomenon essential to everything from shaping an embryo to keeping it free of cancer later in life. When cells refuse to die, and instead multiply uncontrollably, they become what we call tumors. An intricate circuitry of biochemical reactions inside cells coordinates their self-sacrifice. Tracing that circuitry is, naturally, an important part of cancer research.

24 Sep 2012

BioAlliance, Vestiq enter licensing agreement to commercialize Oravig in the US

BioAlliance Pharma SA, an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the execution of the licensing agreement with Vestiq Pharmaceuticals to commercialize Oravig in the United States for the treatment of oropharyngeal candidiasis in adults.

24 Sep 2012

Study to examine SYMPLICITY renal denervation system for treatment-resistant hypertension

The University of Michigan Cardiovascular Center will participate in a national clinical trial to treat the most challenging form of high blood pressure.

24 Sep 2012

Advanced optics system noninvasively maps out network of tiny blood vessels beneath the skin

The trained eye of a dermatologist can identify many types of skin lesions, but human sight only goes so far. Now an international team of researchers has developed an advanced optics system to noninvasively map out the network of tiny blood vessels beneath the outer layer of patients' skin, potentially revealing telltale signs of disease.

24 Sep 2012

Astellas seeks FDA approval for tacrolimus NDA for prophylaxis of organ rejection

Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration seeking approval for tacrolimus extended release capsules for the prophylaxis of organ rejection in adult kidney transplant recipients and adult male liver transplant recipients.

24 Sep 2012

Ohr commences Phase II clinical trial of Squalamine for wet-AMD

Ohr Pharmaceutical today announced the initiation of a Phase II clinical trial to evaluate the efficacy and safety of Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration.

24 Sep 2012

Low levels of vitamin D associated with higher risk of heart attack and early death

New research from the University of Copenhagen and Copenhagen University Hospital shows that low levels of vitamin D are associated with a markedly higher risk of heart attack and early death. The study involved more than 10,000 Danes and has been published in the well-reputed American journal Arteriosclerosis, Thrombosis and Vascular Biology.

24 Sep 2012

RXi completes dosing in RXI-109 Phase 1 study for dermal scarring

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that dosing with their first drug in its first Phase 1 study, was completed last week.

24 Sep 2012

Marijuana and testicular cancer: an interview with Victoria Cortessis

This is a set of malignancies that arise in germ cells of the testicles, the specialized cells that produce sperm. Taken together, testicular cancers are the most common form of malignancy that occurs in young men (approximately 15 to 35 years of age).

24 Sep 2012

BioLineRx receives U.S. patent allowance for BL-1020 to treat schizophrenia

BioLineRx, a biopharmaceutical development company, announced today that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) claiming the crystalline form of BL-1020, a first-in-class orally available treatment for schizophrenia.

24 Sep 2012

Cannabis Science commences CSTATI-1 preclinical studies in Squamous/BCCs, Kaposi's sarcoma

Cannabis Science, a pioneering U.S. Biotech Company developing pharmaceutical products for global public health challenges, is pleased to announce preclinical investigations being initiated in Europe for Squamous/Basal Cell carcinomas and Kaposi's sarcoma based on inhibition of carcinogenicity utilizing cannabinoids that have been demonstrated in recent studies to significantly affect tumor necrosis.

24 Sep 2012

Valeant purchases QLT’s Visudyne

Valeant Pharmaceuticals International, Inc. announced today that it has acquired Visudyne, used to treat abnormal growth of leaky blood vessels in the eye caused by wet age-related macular degeneration, from QLT Inc.

24 Sep 2012

Consuming fish with environmental pollutants can increase risk of cardiovascular diseases

Eat fish, but avoid fish with the most pollutants. This is the conclusion drawn by a group of researchers at Umeå University in Sweden after having weighed the risks of mercury content against the advantages of healthful fatty acids. The work was done as part of an international collaborative effort.

24 Sep 2012

$Encouraging results from CTI’s pacritinib phase 1 study on relapsed/refractory lymphoma$

Encouraging results from CTI’s pacritinib phase 1 study on relapsed/refractory lymphoma

Cell Therapeutics, Inc. announced today that the phase 1 study data of its highly selective oral JAK2 inhibitor pacritinib, or SB1518, showed encouraging anti-tumor activity and good tolerability in 34 patients with relapsed/refractory lymphoma.

24 Sep 2012

Molecular similarity between one sub-type of breast cancer and ovarian cancer

A team of scientists with The Cancer Genome Atlas program reports their genetic characterization of 800 breast tumors, including finding some of the genetic causes of the most common forms of breast cancer, providing clues for new therapeutic targets, and identifying a molecular similarity between one sub-type of breast cancer and ovarian cancer.

24 Sep 2012

Interleukin-6 could affect hunger and satiety

Researchers at the Sahlgrenska Academy, University of Gothenburg, Sweden, have identified a molecule in the immune system that could affect hunger and satiety. The researchers hope that new treatments for obesity will benefit from this finding.

24 Sep 2012

Novel genetic tools may shed new light in papillary thyroid carcinoma research

Next-generation sequencing analyses of the follicular variant of papillary thyroid carcinoma may elucidate the biological underpinnings and clinical behavior of an increasingly common disease, according to data presented at the 82nd ATA Annual Meeting in Québec City, Québec, Canada.

24 Sep 2012

Many survivors of young adult cancers avoid routine medical care due to cost barriers

Many survivors of adolescent and young adult cancers avoid routine medical care because it's too expensive, despite the fact that most have health insurance.

24 Sep 2012

Improvements in trauma care are urgently needed

With traumatic injuries claiming almost six million lives a year, improvements in care, including in the challenging areas of brain and bone injuries, and haemorrhage, are urgently needed.

24 Sep 2012

Medical Condition News

Risk for cardiovascular disease begins early in life

Conceptually novel mechanism for biological regulation of cell suicide

BioAlliance, Vestiq enter licensing agreement to commercialize Oravig in the US

Study to examine SYMPLICITY renal denervation system for treatment-resistant hypertension

Advanced optics system noninvasively maps out network of tiny blood vessels beneath the skin

Astellas seeks FDA approval for tacrolimus NDA for prophylaxis of organ rejection

Ohr commences Phase II clinical trial of Squalamine for wet-AMD

Low levels of vitamin D associated with higher risk of heart attack and early death

RXi completes dosing in RXI-109 Phase 1 study for dermal scarring

Marijuana and testicular cancer: an interview with Victoria Cortessis

BioLineRx receives U.S. patent allowance for BL-1020 to treat schizophrenia

Cannabis Science commences CSTATI-1 preclinical studies in Squamous/BCCs, Kaposi's sarcoma

Valeant purchases QLT’s Visudyne

Consuming fish with environmental pollutants can increase risk of cardiovascular diseases

Encouraging results from CTI’s pacritinib phase 1 study on relapsed/refractory lymphoma

Molecular similarity between one sub-type of breast cancer and ovarian cancer

Interleukin-6 could affect hunger and satiety

Novel genetic tools may shed new light in papillary thyroid carcinoma research

Many survivors of young adult cancers avoid routine medical care due to cost barriers

Improvements in trauma care are urgently needed

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News